PK Exam 2 high level points

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/63

encourage image

There's no tags or description

Looks like no tags are added yet.

64 Terms

1
New cards

Henderson hasselback equation for acids and bases

[A-]/[HA]=1q0^(pH-pKa)

For acid: % unionized = 100 / (1 + 10^(pH − pKa))

<p>[A-]/[HA]=1q0^(pH-pKa)</p><p>For acid: <span>% unionized = 100 / (1 + 10^(pH − pKa))</span></p>
2
New cards

When are bases / acids unionized?

Bases: at high pH (When pH>pKa)
Acids: at low pH (when pH<pKa)

3
New cards

SLC vs ABC transporters

SLC (uptake): PEPT1

ABC (efflux): P-gp, BCRP, MRP2

4
New cards

P-gp inhibitors AND inducers AND substrates

pgp pumps pump away from protected area (to bile in liver, to urine in kidney, to lumen in GI)

Inhibitors: Amiodarone, verapamil, clarithromycin, cyclosporine, Ritonavir (CCRAV)

Inducers: Rifampin, St John's wort, carbamazepine (SCR)

Substrates: Digoxin, dabigatran, loperamide, many anticancer drugs

5
New cards

Effect of Food, PPIs, and H2 blockers on gastric pH

RAISE

matters most for weak bases which need acid to dissolve

6
New cards

Why enteric coatings?

Only dissolve at pH above 5.5-6

7
New cards

Phase I and Phase II

Phase 1: Functionalization- Oxidation, reduction, hydrolysis. Adds or exposes a functional group - CYP450


Phase II: Conjugation- Glucuronidation (UGT), methylation (TPMT), acetylation (NAT2), sulfation (SULT), glutathione (GST). Increases size and polarity.

8
New cards

Grapefruit juice mech

furanocoumarins in grapefruit irreversibly inactivate intestinal CYP3A4

Repeated grapefruit dosing increases effect

Spacing doses does NOT prevent (24 hr effect)

Classic substrates: Felodipine, Simvastatin

9
New cards

Kidney filtration parts

Glomerulus: unbound drug is filtered into the tubule

Proximal tubule: OAT, OCT, P-gp and MRP2 actively secrete drug from the peritubular capillaries

Distal tubule: the unionized form diffuses back into blood; pH-sensitive, so ion trapping is possible

10
New cards

Most polymorphic cyps

CYP2D6, 2C19 and 2C9:

11
New cards

prodrugs

codeine, clopidogrel, tamoxifen, azathioprine

12
New cards

OAT

Organic anion transporters - 12 transmembrane domains with large intracellular loop

OA1 and OAT3 on the basolateral side swap an organic anion for a dicarboxylate

Powered indirectly by the Na⁺ gradient that Na⁺/K⁺-ATPase builds (tertiary active process)

Out to urine: apical efflux by MRP2, MRP4 and BCRP

Substrates: penicillins, methotrexate, loop diuretics, tenofovir, cidofovir

13
New cards

OAT / URAT1 inhibition

(Probenecid, NSAIDS)

→ ^ methotrexate and penicillin levels

Via OAT1/3 and URAT1

Probenecid itself treats gout via URAT1

14
New cards

Organic Anions vs Cations

Anions: OAT1/3 in, MRP2/4 out

Cations: OCT2 in, MATE1/2-K out. Metformin is a key substrate.

Pearl: trimethoprim, cimetidine and dolutegravir block creatinine secretion, so serum creatinine rises without a true fall in GFR (via OCT2 / MATE inh).

15
New cards

CL=IV dose/ AUC and CL=k*Vd and t1/2 depends on Vd / CL

16
New cards

Clinical trial phases

1:Safety, PK and bioavailability; often healthy volunteers

2:Efficacy signal and dose finding in patients

3: Large confirmatory trials

4: postmarketing surveillance

17
New cards

Reading the plasma concentration–time curve

knowt flashcard image
18
New cards

Bioavailability vs bioequivalence

BA: The rate (Cmax/Tmax) and extent (AUC) to which the active ingredient is absorbed and becomes available at the site of action.
BE: A comparison of bioavailability between formulations, products or batches: no significant difference in rate and extent.

19
New cards

Application types

NDA 505(b)(1)

A new drug, with full safety and efficacy data

Human PK and bioavailability of the marketed formulation

NDA 505(b)(2)

A changed product (new formulation, route) relying partly on existing data

Bridging BA/BE study to the listed drug

ANDA 505(j)

A generic copy of a reference listed drug (RLD)

Bioequivalence to the RLD; no new efficacy trials HATCH-WAXMAN act

BLA 351(k)

A biosimilar to a licensed biologic

Analytical, PK and clinical similarity (Purple Book)


20
New cards

Four kinds of "equivalent"

Pharmaceutical equivalents: Same active ingredient (same salt or ester), dosage form, strength and route; meet the same standards. Inactive ingredients may differ.

Bioequivalent: Equivalents or alternatives whose rate and extent of absorption show no significant difference at the same molar dose.

Pharmaceutical alternatives: Same therapeutic moiety, but a different salt, ester, dosage form or strength. Example: doxycycline hyclate vs monohydrate.

Therapeutic equivalents: Pharmaceutical equivalents that are also bioequivalent. Expected to give the same effect and safety: substitutable.

21
New cards

what BE tests

•Formulation and manufacturing variables

•Particle size of the drug

•Chemical form (salt, polymorph)

•Drug solubility

•Compaction pressure during tableting

•Type and amount of excipients

CROSSOVER DESIGN w Healthy individuals, washout period

22
New cards

AUC Cmax Tmax

AUC: Extent, total exposure. Area under the concentration–time curve, time zero to infinity after one dose. Proportional to the amount absorbed.

Cmax: Rate, peak intensity. Peak plasma concentration. Related to the intensity of response and to peak-related toxicity.

Tmax: Rate, speed - Time to peak. Shorter when absorption is faster; hints at how fast the effect begins.

23
New cards

Dosage form absorption speed comparison

Solution>Suspension>Capsule>Tablet> Coated or MR

24
New cards

CI (ci) rule

90% CI sits within 80-125%

Geometric mean ratio for AUC and Cmax

the whole 90% confidence interval for the ratio of average exposure must fall between 80% and 125%

true difference estimated to be 3.5-4% diff AUC/Cmax

25
New cards

BCS

Biopharmaceutics Classification System (for IR oral products)P

Aqueous solubility, intestinal permeability, dissolution

Noyes–Whitney equation is worth recalling: dissolution rate is proportional to surface area times the difference between saturation solubility and bulk concentration

Solubility high if: dissolves completely in ≤ 250 mL of aqueous media over pH 1.2–6.8 at 37 °C

Permeability high if : the extent of absorption in humans is ≥ 85% of the dose (mass balance or absolute bioavailability)

26
New cards

BCS Classes

Class I: High S, High P; limited by gastric emptying

Class II: Low S, High P; limited by dissolution »^ surface area/solvents/surfactants

Class III: High S, Low P; limited by permeability » ^permeability/ max lumenal C

Class IV: Low S, Low P; limited by both

(Solubility on X, Permeability on Y)

<p>Class I: High S, High P; limited by gastric emptying</p><p>Class II: Low S, High P; limited by dissolution »^ surface area/solvents/surfactants</p><p>Class III: High S, Low P; limited by permeability » ^permeability/ max lumenal C</p><p>Class IV: Low S, Low P; limited by both</p><p>(Solubility on X, Permeability on Y)</p>
27
New cards

Log P

<0: Hydrophilic: dissolves well, crosses poorly

1-3: ideal balance

>5: Very lipophilic: solubility limits absorption

P=C(Octanol)/C(water)

28
New cards

Lipinski’s Rule of 5

<500Da, <5log P <5 H bond donors <10 h bond acceptors

(GREATER THAN OR EQUAL TO)
Exceptions for substrates for uptake transporters + natural products

29
New cards

Solubility Boundary + measurement

Highly soluble when: the highest single therapeutic dose dissolves completely in ≤ 250 mL of aqueous buffer, at every pH from 1.2 to 6.8, at 37 ± 1 °C

Thermodynamic (BCS):

•Shake-flask: excess solid drug in buffer at 37 °C

•pH 1.2, 4.5 and 6.8 (and at the pKa)

•Shake until equilibrium, then assay the dissolved drug

Kinetic (discovery)

•Predissolve in DMSO (under 1% final)

•Dilute into buffer at pH 6.5 (intestine) or 7.4 (blood) until it precipitates

•Read optically; high throughput, but can overestimate

30
New cards

Dissolution boundary

Rapid: >85 in 30 min

Very rapid: >85% in 15 min

Apparatus: USP I (basket) at 100 rpm or USP II (paddle) at 50 rpm

Media: ≤ 900 mL at pH 1.2, 4.5 and 6.8, 37 °C

31
New cards

Permeability boundary

High when: the extent of absorption in humans is ≥ 85% of the dose

Peff : Distance moved per unit time (cm/s) across the intestinal wall, from human intestinal perfusion

32
New cards

Permeability in vitro vs clinical human

In vitro: Caco-2 cells: Human colorectal adenocarcinoma cells that grow into an enterocyte-like monolayer with tight junctions and transporters.

Clinical human data: Mass balance, absolute bioavailability, intestinal perfusion. The gold standard, but costly.

Papp (cm/s)

Expected absorption

< 1 × 10⁻⁶

Poor (0–20%)

1–10 × 10⁻⁶

Moderate (20–70%)

> 10 × 10⁻⁶

Well absorbed (70–100%)


33
New cards

Four ways to show BE, in order of preference

Pharmacokinetic study (drug levels in plasma or urine)>

Pharmacodynamic study (measurable drug effect)>

Comparative clinical study (clinical endpoints)>

In vitro

34
New cards

When dissolution can replace an in vivo BE study

Requirement

Class I

Class III

Drug substance

High solubility, high permeability

High solubility, low permeability

Dissolution

Rapid (≥ 85% in 30 min) in test and reference

Very rapid (≥ 85% in 15 min) in test and reference

Excipients

Differences allowed, except those that can affect absorption

Qualitatively the same and quantitatively very similar

EXCEPT: Class II and IV, narrow therapeutic index drugs, modified-release products, and products absorbed in the mouth (buccal, sublingual)

35
New cards

Rescuing poorly soluble Class II and IV drugs

Nanoparticles, More surface area, faster dissolution

Lipid-based systems, Drug stays dissolved in oil and surfactant; self-emulsifies in the gut

solid dispersions, Amorphous drug held in a polymer; dissolves faster than crystals

micelles, Surfactants solubilize drug inside micelle cores

cyclodextrins- Drug sits in a hydrophobic cavity of a soluble ring

36
New cards

What counts as a biological product?

generally large, complex molecules made in a living system - CANNOT BE EXACT COPIES, tested 250 times in production

Therapeutic proteins

Monoclonal antibodies

Vaccines

Blood products / allergenics, cell and gene therapies

VARIABILITY from post-translational cell-driven modifications

37
New cards

Two conditions define a biosimilar

1 · Highly similar 2 · No clinically meaningful differences

38
New cards

Biosimilar terms

Reference product The original FDA-licensed biologic (also called originator or innovator)

Biosimilar Approved under 351(k); can be prescribed by name

Interchangeable A biosimilar that may be substituted at the pharmacy, as state law allows

Outside the US "Biomimics" or non-regulated copies have not met a biosimilar pathway

39
New cards

biosimilar vs generic


Generic

Biosimilar

Made by

Chemical synthesis

Living cells

Sameness

Identical active ingredient

Highly similar; no clinically meaningful differences

Pathway

ANDA, FD&C Act 505(j)

BLA, PHS Act 351(k)

Key evidence

Pharmaceutical equivalence + PK bioequivalence

Analytical, PK/PD, immunogenicity; clinical studies as needed

Listed in

Orange Book

Purple Book

Pharmacy substitution

AB-rated generics

Only interchangeable products


40
New cards

biosimilar four-letter suffix

Tracks adverse events to the exact product, so pharmacovigilance works

41
New cards

Biologics get much longer protection than small molecules

reference biologic exclusivity: 12 yrs

before biosimilar application can be submitted: 4 yrs

small molecule exclusivity: 5 yrs

42
New cards

Small molecule and Biologic abbreviated pathways

Small molecules:

Food, Drug, and Cosmetic Act

Hatch-Waxman Amendments (1984) created the ANDA for generics

Biologics:

The BPCI Act (2010, part of the ACA) created the abbreviated 351(k) pathway

43
New cards

What a 351(k) application must show about the product

Biosimilar

Same mechanism of action

Same conditions of use

Same route, dosage form and strength

-Analytical studies Show the product is "highly similar" despite minor differences in clinically inactive components

-Animal studies Including toxicity, when needed

-Clinical studies Immunogenicity, plus PK or PD, enough to show safety, purity and potency

44
New cards

Interchangeability:

all biosimilars should be interchangeable; designation may become routine

45
New cards

Biologics Open questions and challenges

Immunogenicity Could small differences change anti-drug antibody rates? Compared directly in clinical studies.'

Switching Does alternating products provoke an immune response? Data so far say no.

Traceability Distinct suffixes and brand names so adverse events reach the right product

Uptake Prescriber and patient confidence, the nocebo effect, rebates

46
New cards

Pharmacogenomics vs pharmacogenetics

Pharmacogenomics The study of how genes, across the whole genome, affect a person's response to drugs

Pharmacogenetics The effect of variation in individual genes on drug response: disposition (PK), safety and tolerability, and efficacy

47
New cards

Star (*) alleles

*1 = reference function; numbered alleles = defined variants (PharmVar)

48
New cards

Mutation or polymorphism? Germline or Somatic?

Mutation A permanent change in DNA sequence that differs from most people; often rare

Polymorphism A variant present in at least 1% of a population; most PGx variants

Germline Inherited, in every cell, lifelong: guides dosing (CYP2D6, TPMT)

Somatic Acquired in a tumor only: guides targeted therapy (HER2, EGFR)

49
New cards

Germline variants with prescribing guidance

Gene

Example drugs

Gene

Example drugs

CYP2D6

Codeine, tramadol, tamoxifen, TCAs, atomoxetine

TPMT, NUDT15

Azathioprine, mercaptopurine, thioguanine

CYP2C19

Clopidogrel, SSRIs, voriconazole, PPIs

DPYD

Fluorouracil, capecitabine

CYP2C9, VKORC1

Warfarin, phenytoin, NSAIDs, siponimod

UGT1A1

Irinotecan, atazanavir

CYP3A5

Tacrolimus

HLA-B

Abacavir, carbamazepine, allopurinol

SLCO1B1

Simvastatin and other statins

G6PD

Rasburicase, primaquine, dapsone

CYP2B6

Efavirenz

CFTR

Ivacaftor


50
New cards

CYP2D6 alleles

Allele

Change

Function

where

1xN, 2xN

Gene duplication

Increased

mid east

*4

Splicing defect

None

euro

*5

Gene deletion

None


*10

P34S, S486T

Decreased

E asia

*17

T107I, R296C

Decreased

African

*41

Splicing

Decreased

Afric/eur/M east


51
New cards

Cyp 2D6 activity score/values

1: 1, 2 (normal)

0.5: 9, 17, 29, 41 (decreased)

0.25: *10 (decreased)

0: 3, 4, 5, 6 (none)

Duplication: multiply by copy number

Activity score

Phenotype

0

Poor metabolizer (PM)

0.25–1

Intermediate metabolizer (IM)

1.25–2.25

Normal metabolizer (NM)

> 2.25

Ultrarapid metabolizer (UM)


52
New cards

Strong CYP2D6 inh

Paroxetine, fluoxetine, bupropion, quinidine: convert a normal metabolizer to a poor one

53
New cards

Clopidogrel

needs CYP2C19 to work

2* and 3* less active metabolite

CPIC (2022) recommends prasugrel or ticagrelor for intermediate and poor metabolizers with acute coronary syndrome or PCI, if not contraindicated.

54
New cards

Warfarin

CYP2C9 clears more potent S-warfarin -2*/3* reduce clearance

VKORC1- warfarin’s target- 1639G>A variant lowers expression- more sensitive EAST ASIANS

CYP4F2 - vit K clearance

VKORC1 -1639

CYP2C9 1/1

1/2

1/3

2/2

2/3

3/3

GG

5–7

5–7

3–4

3–4

3–4

0.5–2

AG

5–7

3–4

3–4

3–4

0.5–2

0.5–2

AA

3–4

3–4

0.5–2

0.5–2

0.5–2

0.5–2


55
New cards

HLA

HLA-B*57:01 · abacavir -Hypersensitivity syndrome. Test before every new start;

HLA-B*15:02 · carbamazepine - Stevens–Johnson syndrome and TEN. Test patients with Asian ancestry; also oxcarbazepine, phenytoin.

HLA-B*58:01 · allopurinol - Severe cutaneous reactions. Common in Han Chinese, Korean, Thai and African ancestry.

56
New cards

Transporters

SLCO1B1 (OATP1B1) - Liver uptake of statins. The 5 / 15 variants raise simvastatin levels and myopathy risk; CPIC guideline (2022).**

ABCB1 (MDR1, P-gp) - inconsistent results

ABCG2 (BCRP) - Q141K reduces rosuvastatin efflux - CPIC suggests lower dose

57
New cards

Treat the responders, spare the rest

Drug

Test

Type

Trastuzumab

HER2 overexpression (breast, gastric)

Somatic

Cetuximab, panitumumab

RAS wild-type (colorectal)

Somatic

Osimertinib, erlotinib

EGFR activating mutation (lung)

Somatic

Ivacaftor

Responsive CFTR variant

Germline

Maraviroc

CCR5-tropic HIV

Viral


58
New cards

Pharmacogenomics reaches every specialty

knowt flashcard image
59
New cards

Where to look for PGx in drug labels

Boxed warning (clopidogrel, capecitabine, abacavir) · Indications · Dosage and administration · Warnings · Clinical pharmacology 12.5 Pharmacogenomics

Level

Meaning

Examples

Testing required

Label states or implies the test must be done before use

Abacavir, eliglustat, ivacaftor, siponimod, rasburicase

Testing recommended

Label recommends the test

Carbamazepine (HLA-B*15:02), thiopurines, capecitabine

Actionable PGx

Label describes a dose or drug change but does not ask for testing

Codeine, clopidogrel, celecoxib, citalopram

Informative PGx

Gene affects the drug, but no clinical action follows

Some CYP2D6 substrates with small effects


60
New cards

Patisiran (Onpattro

1st siRNA drug

Patisiran silences transthyretin (TTR) mRNA in the liver for hereditary transthyretin amyloidosis with polyneuropathy

61
New cards

Editing tools

Nucleases: ZFNs, TALENs, CRISPR-Cas9 cut both strands

Repair: NHEJ disrupts a gene; HDR with a template corrects it

62
New cards

mRNA vaccines: the LNP platform at global scale

LNP delivers mRNA; cells make the antigen briefly; mRNA is degraded


63
New cards

Delivery materials

Lipid nanoparticles : Ionizable lipid, helper lipid, cholesterol and PEG-lipid; carry Cas9 mRNA plus guide RNA to the liver

Polymers: PEI, PLGA, chitosan: studied, less clinical success

Hard: Getting beyond the liver: eye, lung, bone marrow

64
New cards

Thiopurines and thiopurine S-methyltransferase

Thiopurines are purine antimetabolites used for acute lymphoblastic leukemia, autoimmune disease, inflammatory bowel disease and transplantation. Azathioprine is a prodrug converted to 6-mercaptopurine (6-MP). 6-MP has two inactivating routes, TPMT methylation and xanthine oxidase, and one activating route through HGPRT to thioguanine nucleotides, which are incorporated into DNA. With little TPMT, more drug goes down the activating path. Interaction point: allopurinol and febuxostat block xanthine oxidase and cause the same problem, so azathioprine doses must be cut by about 75% with allopurinol.

1 is the normal allele; 2, 3A and 3C are the main nonfunctional alleles

<p>Thiopurines are purine antimetabolites used for acute lymphoblastic leukemia, autoimmune disease, inflammatory bowel disease and transplantation. Azathioprine is a prodrug converted to 6-mercaptopurine (6-MP). 6-MP has two inactivating routes, TPMT methylation and xanthine oxidase, and one activating route through HGPRT to thioguanine nucleotides, which are incorporated into DNA. With little TPMT, more drug goes down the activating path. Interaction point: allopurinol and febuxostat block xanthine oxidase and cause the same problem, so azathioprine doses must be cut by about 75% with allopurinol.</p><p><em>1 is the normal allele; </em>2, <em>3A and </em>3C are the main nonfunctional alleles</p>